BRCA1 and cancer: Although most clinical studies confirm BRCA1/BRCA2 loss cancers as sensitive, other genes biologically involved in HRR have been included in clinical trials for metastatic prostate cancer relapsing after castration (metastatic castration-resistant prostate cancer, mCRPC), with variable levels of efficacy14–23.